Arcus Biosciences
RCUS | NYSE
$16.86
-$0.57 (-3.27%)
At close: Nov 16, 2026, 4:00 PM ET
$16.86
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:01 PM ET
Arcus Biosciences Company Profile
Company profile explainedCompany Profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Key Executives
| Name | Position |
|---|---|
| Terry J. Rosen | Co-Founder, Chairman & Chief Executive Officer |
| Robert C. Goeltz | Principal Financial Officer & Chief Financial Officer |
| Alexander Azoy | Chief Accounting Officer |
| Carolyn C. Tang | General Counsel & Corporate Secretary |
| Holli Kolkey | Vice President of Corporate Communications |
| Jonathan Yingling | Chief Scientific Officer |
| Juan Carlos Jaen | Co- Founder & President |
| K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board |
| Pia Eaves | Vice President of Investor Relations & Strategy |
| Richard A. Markus | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K | Current Report |
| Oct 22, 2026 | 424B5 | Filing |
| Oct 21, 2026 | 424B5 | Filing |
| Oct 21, 2026 | 8-K | Current Report |
| Oct 20, 2026 | 8-K | Current Report |
| Sep 28, 2026 | CT ORDER | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13D/A | [Amend] Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
Arcus Biosciences
| Country | United States |
| IPO Date | Mar 14, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 601 |
| CEO | Terry J. Rosen |
Contact Details
3928 Point Eden Way Hayward,
California 94545 United States
Stock Details
| Ticker Symbol | RCUS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001724521 |
| CUSIP Number | 03969F109 |
| ISIN Number | US03969F1093 |
| SIC Code | 2834 |
Recent News
- 12 days ago / zacks.comArcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
- 21 days ago / businesswire.comArcus Biosciences Announces New Employment Inducement Grants
- 26 days ago / businesswire.comArcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
- 26 days ago / businesswire.comArcus Biosciences Announces Commencement of Public Offering of Common Stock
- 27 days ago / seekingalpha.comArcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead
- 27 days ago / seekingalpha.comArcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
- 28 days ago / zacks.comArcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- 2 months ago / businesswire.comArcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
- 2 months ago / seekingalpha.comArcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / seekingalpha.comArcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Add to Watchlist
Select watchlists to add or remove RCUS